Trial Profile

A phase IIb clinical study of PDS-0101 in combination with other immune-modulating agents in HPV16-positive and HIV-positive subjects with high-grade anal intraepithelial neoplasia (anal pre-cancer)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2022 According to an PDS Biotechnology Corporation, updates from this study will be presented at the Oppenheimer's 32nd Annual Virtual Healthcare Conference, 2022.
18 Jan 2022 According to a PDS Biotechnology Corporation media release, data from this trial will be presented at the B. Riley Securities Virtual Oncology Conference, 2022.
29 Apr 2020 According to a PDS Biotechnology Corporation media release, Dr. Julius Strauss, Staff Clinician, will serve as the principal investigator of the phase 2 clinical trial of PDS0101 in advanced HPV-associated cancers

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com